Dexamethasone therapy in COVID‐19 patients: implications and guidance for the management of blood glucose in people with and without diabetes
- 2 August 2020
- journal article
- letter
- Published by Wiley in Diabetic Medicine
- Vol. 38 (1) , e14378
Abstract
The RECOVERY (Randomised Evaluation of COVid‐19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one‐third in ventilated patients and by one‐fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.Keywords
This publication has 3 references indexed in Scilit:
- Practical recommendations for the management of diabetes in patients with COVID-19The Lancet Diabetes & Endocrinology, 2020
- Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID‐19 pandemicDiabetic Medicine, 2020
- Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care groupDiabetic Medicine, 2018